Zura Bio (NASDAQ:ZURA) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report published on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital reduced their price target on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Piper Sandler reissued an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partners assumed coverage on shares of Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.80.

Zura Bio Stock Down 2.5 %

NASDAQ ZURA opened at $2.32 on Tuesday. Zura Bio has a 1-year low of $2.00 and a 1-year high of $6.35. The business’s 50-day simple moving average is $3.52 and its 200-day simple moving average is $3.67.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). On average, equities research analysts predict that Zura Bio will post -0.65 EPS for the current year.

Insider Transactions at Zura Bio

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently modified their holdings of ZURA. AQR Capital Management LLC bought a new stake in Zura Bio in the 2nd quarter valued at about $43,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Zura Bio during the third quarter valued at approximately $46,000. Renaissance Technologies LLC boosted its position in shares of Zura Bio by 51.3% during the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares during the period. SG Americas Securities LLC bought a new position in Zura Bio in the 3rd quarter worth approximately $62,000. Finally, Valence8 US LP acquired a new stake in Zura Bio in the 3rd quarter valued at approximately $71,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.